PAPER PRESENTED AT ECCOMAS-3MBM- MULTISCALE AND

Iacopo Chiodini
A Ospedale Maggiore
Padiglione Granelli

August 2016

Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adheren...

Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk

Boonen, S
Adachi, J D
Man, Z
Cummings, S R
Lippuner, K
Törring, O
Gallagher, J C
Farrerons, J
Wang, A
Franchimont, N
San Martin, J
Grauer, A
McClung, M

January 2011

The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial showed...

Combined Effects of Exercise and Denosumab Treatment on Local Failure in Post-menopausal Osteoporosis-Insights from Bone Remodelling Simulations Accounting for Mineralisation and Damage

Martínez-Reina, Javier
Calvo-Gallego, José L.
Pivonka, Peter

June 2021

Denosumab has been shown to increase bone mineral density (BMD) and reduce the fracture risk in pati...

Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab

Schneiner, S
Pivonka, P
Smith, D
Dunstan, C
Hellmich, C

January 2014

Denosumab, a fully human monoclonal antibody, has been approved for the treatment of postmenopausal ...

Denosumab: Recent update in postmenopausal osteoporosis

Silva, Inês
Branco, Jaime

October 2012

Postmenopausal osteoporosis is a major concern to public health. Fractures are the major clinical co...

Computer simulation-based modeling of the pharmaceutical intervention of postmenopausal osteoporosis by denosumab

Scheiner, S.
Pivonka, P.
Smith, D. W.
Dunstan, C. R.

January 2012

Postmenopausal osteoporosis (PMO), leading to a higher bone fracture risk, is characterized by a sig...

Pharmacotherapy of Bone Loss in Postmenopausal Women: Focus on Denosumab

Alejandro Roman-Gonzalez
Kathryn E. Ackerman

January 2009

Denosumab is a human monoclonal antibody against RANKL. This antibody decreases bone turnover marker...

Effects of long-term treatment of denosumab on bone mineral density: insights from an in-silico model of bone mineralization

Martinez-Reina, Javier
Pivonka, Peter

August 2019

Denosumab is one of the most commonly prescribed anti-resorptive drugs for the treatment of postmeno...

journalsPermissions.nav Therapeutic Advances in Musculoskeletal Disease Review

Ther Adv
Musculoskel Dis

August 2016

A new therapeutic advance in the treatment of postmenopausal osteoporosis is denosumab. Densoumab is...

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Cummings SR
San Martin J
McClung MR
Siris ES
Eastell R
Reid IR
Delmas P
Zoog HB
Austin M
Wang A
Kutilek S
Adami S
Zanchetta J
Libanati C
Siddhanti S
Christiansen C
FREEDOM Trial
Nuti R

January 2009

BACKGROUND: Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear fact...

Integrated Model for Denosumab and Ibandronate Pharmacodynamics in Postmenopausal Women

Dhananjay D. Marathe
Anshu Marathe
Donald E. Mager

October 2015

This study aims to characterize the pharmacodynamic properties of denosumab, a RANK ligand inhibitor...

Spanish Menopause Society position statement: Use of denosumab in postmenopausal women

Cano, Antonio
Silvan, José Manuel
Estévez, Antonio
Baró, Francesc
Villero, José
Quereda Seguí, Francisco José
Ferrer, Javier
Mendoza, Nicolás
Sánchez Borrego, Rafael

September 2014

Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing evidences ...

Denosumab – a new medication in the treatment of postmenopausal osteoporosis

Radosław Słopień
Piotr Rynio
Elżbieta Kubala
Ewa Milewska
Blazej Meczekalski

October 2017

Osteoporosis is a chronic, systemic skeletal disorder characterised by decreased bone density. It le...

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis

Yong-Ki Min

March 2015

Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor...

Critical appraisal of denosumab in the treatment and prevention of postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation

David L Kendler
Kenneth Shawn Davison

September 2010

David L Kendler1, Kenneth Shawn Davison21Prohealth Clinical Research, University of British Columbia...

Open Access Full Text Article

Iacopo Chiodini
A Ospedale Maggiore
Padiglione Granelli

August 2016

Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adheren...

Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk

Boonen, S
Adachi, J D
Man, Z
Cummings, S R
Lippuner, K
Törring, O
Gallagher, J C
Farrerons, J
Wang, A
Franchimont, N
San Martin, J
Grauer, A
McClung, M

January 2011

The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial showed...

Combined Effects of Exercise and Denosumab Treatment on Local Failure in Post-menopausal Osteoporosis-Insights from Bone Remodelling Simulations Accounting for Mineralisation and Damage

Martínez-Reina, Javier
Calvo-Gallego, José L.
Pivonka, Peter

June 2021

Denosumab has been shown to increase bone mineral density (BMD) and reduce the fracture risk in pati...

Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab

Schneiner, S
Pivonka, P
Smith, D
Dunstan, C
Hellmich, C

January 2014

Denosumab, a fully human monoclonal antibody, has been approved for the treatment of postmenopausal ...

Denosumab: Recent update in postmenopausal osteoporosis

Silva, Inês
Branco, Jaime

October 2012

Postmenopausal osteoporosis is a major concern to public health. Fractures are the major clinical co...

Computer simulation-based modeling of the pharmaceutical intervention of postmenopausal osteoporosis by denosumab

Scheiner, S.
Pivonka, P.
Smith, D. W.
Dunstan, C. R.

January 2012

Postmenopausal osteoporosis (PMO), leading to a higher bone fracture risk, is characterized by a sig...

Pharmacotherapy of Bone Loss in Postmenopausal Women: Focus on Denosumab

Alejandro Roman-Gonzalez
Kathryn E. Ackerman

January 2009

Denosumab is a human monoclonal antibody against RANKL. This antibody decreases bone turnover marker...

Effects of long-term treatment of denosumab on bone mineral density: insights from an in-silico model of bone mineralization

Martinez-Reina, Javier
Pivonka, Peter

August 2019

Denosumab is one of the most commonly prescribed anti-resorptive drugs for the treatment of postmeno...

journalsPermissions.nav Therapeutic Advances in Musculoskeletal Disease Review

Ther Adv
Musculoskel Dis

August 2016

A new therapeutic advance in the treatment of postmenopausal osteoporosis is denosumab. Densoumab is...

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Cummings SR
San Martin J
McClung MR
Siris ES
Eastell R
Reid IR
Delmas P
Zoog HB
Austin M
Wang A
Kutilek S
Adami S
Zanchetta J
Libanati C
Siddhanti S
Christiansen C
FREEDOM Trial
Nuti R

January 2009

BACKGROUND: Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear fact...

Integrated Model for Denosumab and Ibandronate Pharmacodynamics in Postmenopausal Women

Dhananjay D. Marathe
Anshu Marathe
Donald E. Mager

October 2015

This study aims to characterize the pharmacodynamic properties of denosumab, a RANK ligand inhibitor...

Spanish Menopause Society position statement: Use of denosumab in postmenopausal women

Cano, Antonio
Silvan, José Manuel
Estévez, Antonio
Baró, Francesc
Villero, José
Quereda Seguí, Francisco José
Ferrer, Javier
Mendoza, Nicolás
Sánchez Borrego, Rafael

September 2014

Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing evidences ...

Denosumab – a new medication in the treatment of postmenopausal osteoporosis

Radosław Słopień
Piotr Rynio
Elżbieta Kubala
Ewa Milewska
Blazej Meczekalski

October 2017

Osteoporosis is a chronic, systemic skeletal disorder characterised by decreased bone density. It le...

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis

Yong-Ki Min

March 2015

Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor...

Critical appraisal of denosumab in the treatment and prevention of postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation

David L Kendler
Kenneth Shawn Davison

September 2010

David L Kendler1, Kenneth Shawn Davison21Prohealth Clinical Research, University of British Columbia...

Open Access Full Text Article

Iacopo Chiodini
A Ospedale Maggiore
Padiglione Granelli

August 2016

Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adheren...

Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk

Boonen, S
Adachi, J D
Man, Z
Cummings, S R
Lippuner, K
Törring, O
Gallagher, J C
Farrerons, J
Wang, A
Franchimont, N
San Martin, J
Grauer, A
McClung, M

January 2011

The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial showed...

Combined Effects of Exercise and Denosumab Treatment on Local Failure in Post-menopausal Osteoporosis-Insights from Bone Remodelling Simulations Accounting for Mineralisation and Damage

Martínez-Reina, Javier
Calvo-Gallego, José L.
Pivonka, Peter

June 2021

Denosumab has been shown to increase bone mineral density (BMD) and reduce the fracture risk in pati...

PAPER PRESENTED AT ECCOMAS-3MBM- MULTISCALE AND

Abstract

Extracted data

PAPER PRESENTED AT ECCOMAS-3MBM- MULTISCALE AND

Abstract

Extracted data

Related items

Related items